We’re tracking in-house compensation. Take the Law360 Survey
Click here
Iron Workers District Council of New England Health and Welfare Fund v. Teva Pharmaceutical Industries Ltd. et al
-
June 08, 2026
Berman Tabacco, Sperling Kenny Nachwalter LLC, Hilliard Shadowen LLP and five other firms have asked a Massachusetts federal judge for $11.55 million in attorney fees from a $35 million antitrust settlement resolving claims that Teva abused patent protections to delay generic competition for its QVAR asthma inhalers.
-
April 02, 2026
A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.
-
October 27, 2025
Teva Pharmaceuticals will pay $35 million to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers, according to a motion for preliminary injunction filed in Massachusetts federal court.
-
August 05, 2025
Teva Pharmaceuticals has settled a 2023 lawsuit by a coalition of union healthcare funds accusing the company of thwarting the introduction of a generic version of its QVAR inhalers to the market, according to a filing in Massachusetts federal court.
-
November 07, 2024
A Massachusetts federal court refused Teva Pharmaceutical Industries Ltd.'s attempt to end a case accusing it of orchestrating a decade-long scheme to delay generic competition for its QVAR asthma inhalers, but cut allegations that Teva paid Amneal Pharmaceuticals Inc. not to launch its version.
-
July 10, 2024
Employee benefit funds accusing Teva of orchestrating a decadelong scheme to delay generic competition for its QVAR asthma inhalers told a Massachusetts federal court the drugmaker is trying to end the case by addressing merely one aspect of a multipart scheme.
-
May 08, 2024
A Massachusetts federal judge largely refused Tuesday to toss antitrust claims accusing Teva of a decadelong anticompetitive scheme to delay generic competition for its blockbuster QVAR asthma inhalers, finding it plausible that Teva paid off a would-be rival and forcibly switched doctors and patients to a new product.
-
May 22, 2023
Teva was hit with a suit on Monday in Massachusetts federal court that alleges the pharmaceutical giant ran a nearly decadelong anticompetitive scheme to delay generic competition for QVAR, its blockbuster line of brand-name asthma inhalers.